CSL — The Flush Before the Recovery?CSL — The Flush Before the Recovery?
CSL is one of Australia’s heavyweight blue-chips, so this is a big map for me.
Technically, price is still recovering inside a damaged higher-timeframe structure, and I’m watching the current rally as a push into resistance rather than a confirmed new bull leg.
Compare with CSL Limited
−7.59 AUD
−3.81 B AUD
23.17 B AUD
478.59 M
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
Company info
Sector
Industry
CEO
Gordon Naylor
Website
Headquarters
Melbourne
Founded
1961
IPO date
Jun 8, 1994
ISIN
AU000000CSL8
FIGI
BBG000BKBNS9
Identifiers
ISIN AU000000CSL8
CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment provides plasma products, gene therapies, and recombinants. The CSL Seqirus segment includes predominantly influenza related products and provides pandemic services to governments. The CSL Vidor segment focuses on the distribution of products in the therapeutic areas of iron deficiency and nephrology. The company was founded on November 2, 1961 and is headquartered in Melbourne, Australia.
CSL Undervalue Gem That Will ReboundCSL Limited (ASX:CSL) has long been considered one of Australia’s premier healthcare stocks, yet recent trading levels suggest it is undervalued relative to its historical benchmarks. Currently hovering around A$100, CSL is priced well below analyst fair value estimates of A$155, reflecting a discou
CSL Grand Supercycle Correction Over?They used to say "never sell CSL", they were right up until it peaked on March 2020. This was at the height of the Covid dump, whilst other stocks crashed; CSL was putting in a supercycle top. If you didn't sell the top, you are now down 72% since the all time high. Ouch!
CSL is not any old stock,
CSL Limited (ASX:CSL)One of the strongest “moat” businesses on the ASX because it operates in a niche of healthcare that is extremely difficult, expensive, and slow for competitors to replicate.
1. Plasma collection network (huge barrier to entry)
CSL is one of only a few global companies dominating plasma-derived ther
CSL GOES "SHAKE IT. BAKE IT. BOOTY QUAKE IT. ROLL IT AROUND".CSL Ltd is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions.
CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in va
Epic Grand Supercycle CorrectionWe are witnessing an epic grand supercycle correction in one of the best performing stocks over the last couple of decades. This stock went vertical for 14 years, but what goes up must come down. This stock is owned by many Australian investors, I understand it to be a top 5 name in the Australian s
Never Sell CSL?In the Australian stock market, for years and years there was a saying:
“Never sell CSL.”
This informal mantra was common among investors and brokers and reflected CSL Limited’s reputation as a blue-chip, defensive, growth-and-dividend stock. The idea was that CSL’s business in plasma-derived th
Time to enter ASX:CSL ⁉️Last week, CSL management received positive feedback and the stock is currently in a base. While there is no confirmation of a new trend, the risk-reward ratio is favorable to add a small amount and let the market guide for further additions. I will only add up to 50% of my position in the low base,
Australias CSL Trading in a range on the monthly.Not one I am personally trading at the moment, but CSL was one of the most reliable stocks on the Australian market for years. Since 2020 though it has been stuck in this sideways range that could be good for the worlds slowest swing trade :)
Being towards the bottom of the range might mean there i
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Maturity dateApr 27, 2062
Coupon4.95% (Fixed)
Maturity dateApr 27, 2042
Coupon4.63% (Fixed)
Maturity dateApr 27, 2032
Coupon4.25% (Fixed)
Maturity dateApr 27, 2029
Coupon4.05% (Fixed)
See all CSL bonds
Frequently asked questions
The current price of CSL is 174.50 AUD — it has decreased by −0.57% in the past 24 hours. Watch CSL Limited stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange CSL Limited stocks are traded under the ticker CSL.
CSL stock has risen by 1.34% compared to the previous week, the month change is a 35.45% rise, over the last year CSL Limited has showed a −15.79% decrease.
We've gathered analysts' opinions on CSL Limited future price: according to them, CSL price has a max estimate of 206.86 AUD and a min estimate of 131.56 AUD. Watch CSL chart and read a more detailed CSL Limited stock forecast: see what analysts think of CSL Limited and suggest that you do with its stocks.
CSL stock is 1.99% volatile and has beta coefficient of 0.97. Track CSL Limited stock price on the chart and check out the list of the most volatile stocks — is CSL Limited there?
Today CSL Limited has the market capitalization of 84.05 B, it has decreased by −0.08% over the last week.
Yes, you can track CSL Limited financials in yearly and quarterly reports right on TradingView.
CSL Limited is going to release the next earnings report on Feb 9, 2027. Keep track of upcoming events with our Earnings Calendar.
CSL earnings for the last half-year are 3.27 AUD per share, whereas the estimation was 3.40 AUD, resulting in a −4.02% surprise. The estimated earnings for the next half-year are 5.54 AUD per share. See more details about CSL Limited earnings.
CSL Limited revenue for the last half-year amounts to 10.79 B AUD, despite the estimated figure of 10.27 B AUD. In the next half-year revenue is expected to reach 11.69 B AUD.
CSL net income for the last half-year is −4.24 B AUD, while the previous report showed 611.97 M AUD of net income which accounts for 0.00% change. Track more CSL Limited financial stats to get the full picture.
Yes, CSL dividends are paid semi-annually. The last dividend per share was 1.81 AUD. As of today, Dividend Yield (TTM)% is 2.43%. Tracking CSL Limited dividends might help you take more informed decisions.
As of Sep 5, 2026, the company has 29 K employees. See our rating of the largest employees — is CSL Limited on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CSL Limited EBITDA is 7.49 B AUD, and current EBITDA margin is 32.18%. See more stats in CSL Limited financial statements.
Like other stocks, CSL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CSL Limited stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CSL Limited technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CSL Limited stock shows the sell signal. See more of CSL Limited technicals for a more comprehensive analysis.









